# Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Source: https://onco.cc/trials/nct06824168/  
OnCo record `nct06824168` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Quizartinib in acute myeloid leukaemia, run by Daiichi Sankyo, now recruiting.

## Summary

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission is a phase 2 interventional study registered as NCT06824168 by Daiichi Sankyo, with 130 participants planned, started 2025-07-18 and due to reach its primary completion in 2028-06-06. Interventions recorded: Quizartinib High Dose and Quizartinib Low Dose.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06824168
- Phase: 2
- Setting: A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission
- Sponsor: Daiichi Sankyo
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06824168: https://clinicaltrials.gov/study/NCT06824168

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Quizartinib](https://onco.cc/drugs/quizartinib/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06824168.json